Identification, course, and treatment of depression after admission for a cardiac condition: rationale and patient characteristics for the identifying depression as a comorbid condition (IDACC) project

Cheok, Frida; Schrader, G.; Banham, David; Marker, Julie; Hordacre, Ann Louise

doi:10.1016/s0002-8703(03)00481-2

Cited by 69 publications

(60 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depression is related to a high risk of suicide and elevated mortality, impaired psychosocial function and reduced QoL. This is consistent with other reports of depression occurring in the context of somatic illness, in which 20-50% of patients are found to suffer depressive episodes -for example, after myocardial infarction, stroke, cancer and diabetes mellitus [74,75,76]. From these studies, we have learned that co-morbid untreated depression might reduce both the prognosis of the somatic illness and the patient's QoL.…”

Section: Psychiatric and Cognitive Dysfunction And Functional Involvesupporting

confidence: 89%

Neurological Complications of Anderson-Fabry Disease

Tuttolomondo

Pecoraro²,

Simonetta³

et al. 2013

CPD

View full text Add to dashboard Cite

Characteristic clinical manifestations of AFD such as acroparesthesias, angiokeratoma, corneal opacity, hypo/ and anhidrosis, gastrointestinal symptoms, renal and cardiac dysfunctions can occur in male and female patients, although heterozygous females with AFD usually seem to be less severely affected. The most prominent CNS manifestations consist of cerebrovascular events such as transient ischaemic attacks (TIAs) and (recurrent) strokes. For the most part, CNS complications in AFD have been attributed to cerebral vasculopathy, including anatomical abnormalities. The natural history of Fabry patients includes transitory cerebral ischaemia and strokes, even in very young persons of both genders. The mechanism is partly due to vascular endothelial accumulation of Gb-3. White matter lesions (WML) on occur MRI. Both males and females can be safely treated with enzyme replacement; and thus screening for Fabry disease of young stroke populations should be considered. There are, however, no hard data of treatment effect on mortality and morbidity. Stroke in Anderson-Fabry disease study of 721 patients with cryptogenic stroke, aged 18-55 years, showed a high prevalence of Fabry disease in this group: 5% (21/432) of men and 3% (7/289) of women. Combining results of both sexes showed that 4% of young patients with stroke of previously unknown cause had Fabry disease, corresponding to about 1-2% of the general population of young stroke patients. Cerebral micro- and macro-vasculopathy have been described in Fabry disease. Neuronal globotriaosylceramide accumulation in selective cortical and brain stem areas including the hippocampus has been reported by autopsy studies in FD, but clinical surrogates as well as the clinical relevance of these findings have not been investigated so far. Another Neurologic hallmark of Fabry disease (FD) includes small fiber neuropathy as well as cerebral micro- and macroangiopathy with premature stroke. Cranial MRI shows progressive white matter lesions (WML) at an early age, increased signal intensity in the pulvinar, and tortuosity and dilatation of the larger vessels. Conventional MRI shows a progressive load of white matter lesions (WMLs) due to cerebral vasculopathy in the course of FD. Another study has been conducted to quantify brain structural changes in clinically affected male and female patients with FD. The peripheral neuropathy in Fabry disease manifests as neuropathic pain, reduced cold and warm sensation and possibly gastrointestinal disturbances. Patients with Fabry disease begin having pain towards the end of the first decade of life or during puberty. Children as young as 6 years of age have complained of pain often associated with febrile illnesses with reduced heat and exercise tolerance. The patients describe the pain as burning that is often associated with deep ache or paresthesiae. Some patients also have joint pain. A high proportion of patients with Fabry disease is at increased risk of developing neuropsychiatric symptoms, such as depression and neuropsychological...

show abstract

Section: Psychiatric and Cognitive Dysfunction And Functional Involvesupporting

confidence: 89%

Neurological Complications of Anderson-Fabry Disease

Tuttolomondo

Pecoraro²,

Simonetta³

et al. 2013

CPD

View full text Add to dashboard Cite

show abstract

“…These professionals should enhance their level of clinical suspicion for post-MI depression [20]; they often have to rely on their intuition, and depression often goes unrecognized in MI patients [19]. One third of patients may also experience anxiety at the time of the cardiac event; in contrast, only 1 out of 3 anxious patients are asked about such symptoms [8] and anxiety is largely ignored in depressed patients [35].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, depression often goes unrecognized in MI patients [19] and health care workers should enhance the level of clinical suspicion for depression in these patients [20]. However, our methods for screening post-MI depression must be improved by using a limited number of questions [21], and the best way to accomplish this remains to be defined [19].…”

Section: Introductionmentioning

confidence: 99%

Recognizing Increased Risk of Depressive Comorbidity after Myocardial Infarction: Looking for 4 Symptoms of Anxiety-Depression

Denollet

Strik

Lousberg

et al. 2006

Psychother Psychosom

View full text Add to dashboard Cite

Background: Screening for depression in myocardial infarction (MI) patients must be improved: (1) depression often goes unrecognized and (2) anxiety has been largely overlooked as an essential feature of depression in these patients. We therefore examined the co-occurrence of anxiety and depression after MI, and the validity of a brief mixed anxiety-depression index as a simple way to identify post-MI patients at increased risk of comorbid depression. Methods: One month after MI, 176 patients underwent a psychiatric interview and completed the Beck Depression Inventory (BDI) and the Symptoms of Anxiety-Depression index (SAD₄) containing four symptoms of anxiety (tension, restlessness) and depression (feeling blue, hopelessness). Results: Thirty-one MI patients (18%) had comorbid depression and 37 (21%) depressive or anxiety disorder. High factor loadings and item-total correlations (SAD₄, α = 0.86) confirmed that symptoms of anxiety and depression co-occurred after MI. Mixed anxiety-depression (SAD₄≧3) was present in 90% of depressed MI patients and in 100% of severely depressed patients. After adjustment for standard depression symptoms (BDI; OR = 4.4, 95% CI 1.6–12.1, p = 0.004), left ventricular ejection fraction, age and sex, mixed anxiety-depression symptomatology was associated with an increased risk of depressive comorbidity (OR = 11.2, 95% CI 3.0–42.5, p < 0.0001). Mixed anxiety-depression was also independently associated with depressive or anxiety disorder (OR = 9.2, 95% CI 3.0–27.6, p < 0.0001). Conclusions: Anxiety is underrecognized in post-MI patients; however, the present findings suggest that anxiety symptomatology should not be overlooked in these patients. Depressive comorbidity after MI is characterized by symptoms of mixed anxiety-depression, after controlling for standard depression symptoms. The SAD₄ represents an easy way to recognize the increased risk of post-MI depression.

show abstract

“…The study protocol has been previously published [28] and only patients with confirmed CHD were included in the analysis. This was defined by hospital admission or documented history of myocardial infarction, unstable angina, coronary artery bypass grafting or percutaneous coronary intervention.…”

Section: Idacc Cohortmentioning

confidence: 99%